MK 3866

Drug Profile

MK 3866

Alternative Names: MK-3866

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 03 Oct 2017 Merck Sharp & Dohme plans the MK-3866-006 phase I trial in Healthy volunteers (NCT03295266)
  • 01 Sep 2017 Phase-I clinical trials in Bacterial infections in USA (IV) (NCT03259087)
  • 21 Aug 2017 Preclinical trials in Bacterial infections in USA (IV) before August 2017 (NCT03259087)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top